Search Immortality Topics:

Page 474«..1020..473474475476..480490..»


Category Archives: Biotechnology

Research and Markets: US Biotechnology Industry: Sector Report – Market Size and Key Trends

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/nngzvh/us_biotechnology_i) has announced the addition of the "US Biotechnology Industry: Sector Report" report to their offering.

This industry profile is an essential tool to help your company gain an in-depth knowledge and competitive advantage in the industry. The profile is an assimilation of insider knowledge, market characteristics and economic indicators. It analyzes the critical success factors in the industry - how the industry has evolved and how competitive dynamics have impacted market behavior.

Sectional Highlights

-- Structure of the industry, market size, and growth rates have been analyzed

-- Value chain analysis categorizes the value-adding activities to develop low-cost differentiation strategies

-- Trend analysis detects historical patterns that could help in forecasting future demand periods

-- Critical issues are reviewed that may become a threat to the industry

-- PEST analysis uses a framework of external factors for macro-environmental scanning of the industry to help in taking advantage of opportunities and making contingency plans for threats

-- Competitive positioning of the industry leaders has been evaluated in terms of sales, profitability, stock trend and other performance indicators

Go here to read the rest:
Research and Markets: US Biotechnology Industry: Sector Report - Market Size and Key Trends

Posted in Biotechnology | Comments Off on Research and Markets: US Biotechnology Industry: Sector Report – Market Size and Key Trends

Research and Markets: Biotechnology Reagents Market by Technology, Applications and End-Users – Current Trends …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/vg7gkl/biotechnology_reag) has announced the addition of the "Biotechnology Reagents Market by Technology, Applications and End-Users - Current Trends, Opportunities and Global Forecasts to 2016" report to their offering.

The biotechnology reagent market is vast; it consists of several technologies such as PCR, cell culture, IVD, expression and transfection, chromatography, spectrometry, electrophoresis, and flow cytometry. This report studies the biotechnology reagents market, by technology, end-users, and applications. The biotechnology reagents market, by technology studied in this report are segmented as life science reagents and analytical reagents; of which life science segment accounted for the largest share of 59.37% of the total market in 2011. The global biotechnology reagents market was valued at $40.3 billion in 2011 and is expected to reach $59.3 billion by 2016; growing at a CAGR of 8% from 2011 to 2016.

The biotechnology reagents market is driven by the increasing use of reagents in therapeutics, basic research and commercial applications. The demand for biotechnology reagents is mainly dependent upon the growth of the biotechnology instrumentation market. The biotechnology instrumentation market continues to witness significant growth due to an increase in the number of biotechnology firms around the globe and increase in research and development expenditure by the biotechnology companies, thus augmenting the demand for biotechnology instruments. Continual product developments are being witnessed in various industries, such as pharmaceutical/bio-pharmaceutical, agri-biotech, and food and beverages; this is expected to facilitate market growth.

North America dominated the biotechnology reagents market with 46.28% share in 2011. Successful completion of the first phase of the Human Genome Project, ahead of schedule, has given rise in the U.S. reagent market. Investments, government funding, and new products are driving the reagents market in the U.S. The Asian market, however, shows greater opportunities, when compared to other regions, with the highest CAGR of 11.8% from 2011 to 2016; due to increased research outsourcing activities in the life technology field.

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Overview

4 Life Sciences & Analytical Reagents Market, By Technology

See the original post here:
Research and Markets: Biotechnology Reagents Market by Technology, Applications and End-Users - Current Trends ...

Posted in Biotechnology | Comments Off on Research and Markets: Biotechnology Reagents Market by Technology, Applications and End-Users – Current Trends …

Onyx Pharmaceuticals and Sarepta Therapeutics Showing Investors Strong Gains in 2012 – Biotech Industry Booming

NEW YORK, NY--(Marketwire -07/26/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Onyx Pharmaceuticals, Inc. (ONXX) and Sarepta Therapeutics Inc. (SRPT).

Access to the full company reports can be found at: http://www.ParagonReport.com/ONXX http://www.ParagonReport.com/SRPT

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company recently announced that the U.S. Food and Drug Administration (FDA) have granted accelerated approval of Kyprolis. Shares of the company are up over 70 percent year-to-date.

Sarepta Therapeutics -- formerly AVI BioPharma -- is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Shares of the company soared over 140 percent after they released positive clinical results for their lead drug candidate eteplirsen.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Follow this link:
Onyx Pharmaceuticals and Sarepta Therapeutics Showing Investors Strong Gains in 2012 - Biotech Industry Booming

Posted in Biotechnology | Comments Off on Onyx Pharmaceuticals and Sarepta Therapeutics Showing Investors Strong Gains in 2012 – Biotech Industry Booming

Research and Markets: 2012 Report on the $90 Billion US Biotechnology Product Manufacturing Industry

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/7gb7zj/biotechnology_prod) has announced the addition of the "Biotechnology Product Manufacturing" report to their offering.

The US biotechnology product manufacturing industry includes about 1,500 companies with combined annual revenue of more than $90 billion. Major companies include Amgen, Biogen Idec, Genentech (owned by Switzerland-based Roche), Genzyme, Life Technologies, and Monsanto. Because many drugs are now developed using biotechnology, the biotechnology and pharmaceutical industries overlap considerably. Related profiles include Biotechnology Research Services, Crop Production, and Pharmaceutical Manufacturing.

The global biotechnology industry includes about 7,000 companies with total revenues of $140 billion. Top regions for biotechnology include the US and Canada, Australia, and Europe, according to Ernst & Youngs Beyond Borders Global Biotechnology Report. Top companies include CSL Limited (Australia), Cangene (Canada), Galapagos nv (Belgium), and ADIMMUNE (Taiwan), as well as the biotech research arms of major international pharmaceutical companies including Novo Nordisk and Sanofi.

COMPETITIVE LANDSCAPE

Demand for biotechnology in the fields of medicine, agriculture, food, and science is driven by insurers' willingness to pay for new medical treatments, the global need to produce more food for a rapidly expanding population, and scientists' desire to find solutions for complex scientific and medical issues. Funding for biotech research is often provided by venture capital funds hoping to cash in on new products. The profitability of individual companies depends on the discovery and effective marketing of new products.

Key Topics Covered:

Industry Overview

Quarterly Industry Update

Business Challenges

Read the rest here:
Research and Markets: 2012 Report on the $90 Billion US Biotechnology Product Manufacturing Industry

Posted in Biotechnology | Comments Off on Research and Markets: 2012 Report on the $90 Billion US Biotechnology Product Manufacturing Industry

Biotechnology Reagents Market by Technology (PCR, Cell Culture, Expression & Transfection, Chromatography, Mass …

NEW YORK, July 26, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biotechnology Reagents Market by Technology (PCR, Cell Culture, Expression & Transfection, Chromatography, Mass Spectrometry, Electrophoresis, & Flow Cytometry), Applications (Protein Purification, Gene Expression, DNA & RNA Analysis, & Drug Testing) and

http://www.reportlinker.com/p0938971/Biotechnology-Reagents-Market-by-Technology-PCR-Cell-Culture-Expression--Transfection-Chromatography-Mass-Spectrometry-Electrophoresis--Flow-Cytometry-Applications-Protein-Purification-Gene-Expression-DNA--RNA-Analysis--Drug-Testing-and.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

Biotechnology reagents are the substances or compounds used to detect or synthesize another substance in order to provide a test reading. These reagents are used in the field of research, diagnosis, bioscience, and education.

The biotechnology reagent market is vast; it consists of several technologies such as PCR, cell culture, IVD, expression and transfection, chromatography, spectrometry, electrophoresis, and flow cytometry. This report studies the biotechnology reagents market, by technology, end-users, and applications. The biotechnology reagents market, by technology studied in this report are segmented as life science reagents and analytical reagents; of which life science segment accounted for the largest share of 59.37% of the total market in 2011. The global biotechnology reagents market was valued at $40.3 billion in 2011 and is expected to reach $59.3 billion by 2016; growing at a CAGR of 8% from 2011 to 2016.

The biotechnology reagents market is driven by the increasing use of reagents in therapeutics, basic research and commercial applications. The demand for biotechnology reagents is mainly dependent upon the growth of the biotechnology instrumentation market. The biotechnology instrumentation market continues to witness significant growth due to an increase in the number of biotechnology firms around the globe and increase in research and development expenditure by the biotechnology companies, thus augmenting the demand for biotechnology instruments. Continual product developments are being witnessed in various industries, such as pharmaceutical/bio-pharmaceutical, agri-biotech, and food and beverages; this is expected to facilitate market growth.

North America dominated the biotechnology reagents market with 46.28% share in 2011. Successful completion of the first phase of the Human Genome Project, ahead of schedule, has given rise in the U.S. reagent market. Investments, government funding, and new products are driving the reagents market in the U.S. The Asian market, however, shows greater opportunities, when compared to other regions, with the highest CAGR of 11.8% from 2011 to 2016; due to increased research outsourcing activities in the life technology field.

Major players in the global biotechnology reagents market include Life Technologies, (U.S.), Bio-Rad (U.S.), Thermo Fisher Scientific (U.S.), Water Corporation (U.S.), Sigma-Aldrich (U.S.), Agilent Technologies Inc. (U.S.), Betcon Dickinson (U.S.), Beckman Coulter (U.S.), Roche (Switzerland), and Abbott (U.S.).

Scope of the Report

This biotechnology reagents market report will enable strategic understanding of the following key segments of the market:

Read the rest here:
Biotechnology Reagents Market by Technology (PCR, Cell Culture, Expression & Transfection, Chromatography, Mass ...

Posted in Biotechnology | Comments Off on Biotechnology Reagents Market by Technology (PCR, Cell Culture, Expression & Transfection, Chromatography, Mass …

Despite Facing More Challenging Regulation Process Biotech Companies Showing Impressive Growth in 2012

NEW YORK, NY--(Marketwire -07/25/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Aastrom Biosciences, Inc. (ASTM) and Geron Corporation (GERN).

Access to the full company reports can be found at: http://www.ParagonReport.com/ASTM http://www.ParagonReport.com/GERN

Despite having to negotiate a more challenging regulation process, biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Aastrom Biosciences is dedicated to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently evaluating its autologous cellular therapies in late-stage U.S. clinical trials in the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). These critical diseases are associated with significant morbidity and mortality and very limited treatment options.

Geron is a biopharmaceutical company developing first-in-class therapies for cancer. The company has two lead product candidates in clinical development, imetelstat and GRN1005. Imetelstat is a telomerase inhibitor that is being evaluated in four Phase 2 clinical trials. GRN1005 is a peptide-drug conjugate that is designed to transport a proven anti-cancer drug, paclitaxel.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

See the original post:
Despite Facing More Challenging Regulation Process Biotech Companies Showing Impressive Growth in 2012

Posted in Biotechnology | Comments Off on Despite Facing More Challenging Regulation Process Biotech Companies Showing Impressive Growth in 2012